Calico, Google 's anti-aging subsidiary, has announced disappointing results from its first-ever drug trial. The experimental ...

Fosigotifator, an amyotrophic lateral sclerosis drug developed by Calico Life Sciences, a biotech company backed by Google's parent company Alphabet, failed to meet its primary endpoint ...

Calico’s fosigotifator was tested for amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease that affects nerve cells in the brain and spinal cord and leads to paralysis.

Google’s (GOOGL) anti-aging company Calico released disappointing trial results of its first ever drug. Calico’s fosigotifator was tested for amyotrophic lateral sclerosis (ALS), a fatal ...

Massachusetts General Hospital found neither AbbVie and Calico’s fosigotifator nor Denali’s DNL343 significantly slowed disease progression, causing misses on their respective primary endpoints.

(Cell Reports) Topline results from a HEALEY platform trial showed that fosigotifator, an investigational eIF2B activator developed by the longevity company Calico Life Sciences in collaboration ...

The first data have now emerged from a drug Calico developed. It failed. The pill, known as fosigotifator, was not designed to slow aging itself. The Food and Drug Administration does not consider ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.